氯美卡因 | 13930-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯美卡因
• 英文名称: 3-amino-4-chloro-benzoic acid-(2-dimethylamino-ethyl ester)
• 英文别名: 3-Amino-4-chlor-benzoesaeure-(2-dimethylamino-aethylester)；Clormecaine；2-(dimethylamino)ethyl 3-amino-4-chlorobenzoate
• CAS: 13930-34-2
• 化学式: C₁₁H₁₅ClN₂O₂
• mdl: MFCD00868461
• 分子量: 242.705
• InChiKey: BMDZNGISRKXXIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
  申请人：Vyteris, Inc.

  公开号：EP1586347A1

  公开（公告）日：2005-10-19

  Highly shelf-stable electrically assisted transdermal drug delivery systems for deliverir g epinephrine, typically with an anesthetic such as lidocaine, are provided along with methods for making the highly shelf-stable epinephrine-containing transdermal deliver device. Highly shelf-stable packaged electrode assemblies for transdermal delivery of epinephrine also are provided.

  提供了用于输送肾上腺素（通常与利多卡因等麻醉剂一起）的高货架稳定性电辅助透皮给药系统，以及制造高货架稳定性含肾上腺素透皮给药装置的方法。还提供了用于透皮给药肾上腺素的高货架稳定性包装电极组件。
• Hyaluronic acid composition
  申请人：Q-Med AB

  公开号：EP2484387A1

  公开（公告）日：2012-08-08

  The present invention relates to an injectable hyaluronic acid composition comprising a hyaluronic acid; a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative. The present invention further relates to the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

  本发明涉及一种可注射的透明质酸组合物，该组合物包括透明质酸；一种局麻药，该局麻药选自由酰胺类和酯类局麻药组成的组或其组合；以及一种抗坏血酸衍生物。本发明还涉及这种组合物的医疗和非医疗用途，如美容用途，以及制造这种组合物的方法。
• HYALURONIC ACID COMPOSITION
  申请人：Q-Med AB

  公开号：EP2954907A1

  公开（公告）日：2015-12-16

  The present invention relates to an injectable hyaluronic acid composition comprising a hyaluronic acid; a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G' of the composition caused by the local anesthetic upon sterilization by heat. The present invention further relates to the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

  本发明涉及一种可注射的透明质酸组合物，该组合物包含透明质酸；选自酰胺类和酯类局麻药或其组合的局麻药；以及抗坏血酸衍生物，抗坏血酸衍生物的用量可防止或减少局麻药在加热灭菌时对组合物粘度和/或弹性模量G'的影响。本发明还涉及这种组合物的医疗和非医疗用途，例如化妆品用途，以及制造这种组合物的方法。
• Fast dissolving pharmaceutical composition
  申请人：Ferring B.V.

  公开号：US10023335B2

  公开（公告）日：2018-07-17

  The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

  本发明涉及一种药物组合物，该组合物包含一种携带有药物活性成分的开放式基质网络，其中开放式基质网络包括利凡。